Floatz logo

bg-60366

EGFR Activating Mutation

BeOne MedicinesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the EGFR Activating Mutation cohort.

Asset / SponsorPhaseRating
Carboplatin
Juntendo University
Phase 4BB
Osimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
ty-9591
TYK Medicines, Inc
Phase 3BB
Gefetinib
Sichuan University
Phase 4BB
Famitinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 21 →

Same molecule, other indications

bg-60366 is also rated in:

EGFR Mutation-Related TumorsDormant
CC
Indicative ·
43 / 100
View asset →
lung cancerDormant
C
Indicative ·
37 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →